The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: the complete task force report

Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Fertility and sterility (Impact Factor: 4.59). 11/2008; 91(2):456-88. DOI: 10.1016/j.fertnstert.2008.06.035
Source: PubMed


To review all available data and recommend a definition for polycystic ovary syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to guide clinical diagnosis and future research.
Literature review and expert consensus.
Professional society.
A systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, to identify studies evaluating the epidemiology or phenotypic aspects of PCOS.
The Task Force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by the Androgen Excess and PCOS (AE-PCOS) Society AE-PCOS Board of Directors. No section was finalized until all members were satisfied with the contents, and minority opinions noted. Statements were not included that were not supported by peer-reviewed evidence.
Based on the available data, it is the view of the AE-PCOS Society Task Force that PCOS should be defined by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of related disorders. However, a minority considered the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism, but recognized that more data are required before validating this supposition. Finally, the Task Force recognized and fully expects that the definition of this syndrome will evolve over time to incorporate new research findings.

Download full-text


Available from: Didier Dewailly,
  • Source
    • "The ratio of the irregular PCOS women in the present study is within the recorded ratio in papers from different societies[27]. The disturbances in the periods of women may reflect hormonal changes that cause ovulation disturbances or associated with the multiple small follicles of the polycystic ovaries [28]. "

  • Source
    • "The definition of polycystic ovaries was previously described [17]. PCOS was diagnosed according to the Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome [18], which require the presence of hyperandrogenism and ovarian dysfunction. Serum ferritin levels were obtained in all 539 women, and the median level was 45.5 ng/mL. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study is to evaluate serum ferritin levels and polycystic ovary syndrome (PCOS)-related complications in obese and nonobese women. Materials and methods: This retrospective study included 539 (286 with PCOS and 253 without PCOS). Results: Serum ferritin correlated with menstrual cycle length, sex hormone-binding globulin, total testosterone, androstenedione, triglyceride, and total cholesterol in both obese and nonobese women. Obese women with high ferritin levels exhibited higher insulin resistance, impaired glucose tolerance, and liver enzymes (glutamic oxaloacetic transaminase, glutamic pyruvic transaminase) than obese women with low ferritin levels. However, among nonobese women, insulin resistance and risk of diabetes were not significantly different between the high and low ferritin groups. Independent of obesity, hypertriglyceridemia was the major metabolic disturbance observed in women with elevated serum ferritin levels. Conclusion: Elevated serum ferritin levels are associated with increased insulin resistance and risk of diabetes in obese women but not in nonobese women. However, higher serum ferritin levels were correlated with a greater risk of hyperglyceridemia in both obese and nonobese women. Therefore, hypertriglyceridemia in women with PCOS might be associated with iron metabolism.
    China An International Journal 08/2015; 54(4). DOI:10.1016/j.tjog.2014.06.005 · 0.18 Impact Factor
    • "Accordingly, PCOS is diagnosed when two of the following criteria are present: oligo-/amenorrhea , clinical and/or biochemical signs of HA and PCOM on ultrasound . The Androgen Excess and PCOS Society (AE-PCOS) published the most recent definition in 2006 suggesting to involve the presence of HA (clinical and/or biochemical) and ovarian dysfunction [oligoanovulation (OA) and/or PCO] (Azziz et al., 2009). Thus, there are different phenotypes of PCOS, which are subject of intense debate (Table I; Carmina et al., 2005; Chang et al., 2005; Shroff et al., 2007; Palomba et al., 2010; Palomba et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Does the prevalence of adverse maternal and neonatal outcomes vary in women diagnosed with polycystic ovary syndrome (PCOS) according to different definitions? A comparison of different criteria revealed that there is a substantial risk for perinatal complications in PCOS women, regardless of the used definition. Pregnant women with PCOS are susceptible to perinatal complications. At present, there are three main definitions for PCOS. So far, we are aware of only one study, which found that the elevated risk for complications varied widely depending on the different phenotypes and features but only considered a relatively small sample size for some of the phenotypes. Retrospective matched cohort study. Data of primiparous women with PCOS according to ESHRE/ASRM 2003 criteria and healthy controls giving birth to neonates ≥500 g were included. A total of 885 women were analysed: out of 177 women with PCOS, 85 (48.0%) met the National Institutes of Health (NIH) 1990 criteria, another 14 (7.9%) featured the additional phenotypes defined by The Androgen Excess and PCOS Society (AE-PCOS) 2006 criteria, 78 (44.1%) were classified as PCOS exclusively by the ESHRE/ASRM 2003 definition, and 708 represented the control group. The prevalence of adverse maternal (49.4 versus 64.3 versus 60.3%, P = 0.313) and neonatal (27.1 versus 35.7 versus 23.1%, P = 0.615) outcomes did not differ within the three PCOS groups (ESHRE/ASRM, NIH, AE-PCOS, respectively). Compared with healthy controls, the risk for maternal complications was increased in PCOS patients [odds ratio (OR) 2.57; 95% confidence interval (CI) 1.82-3.64; P < 0.001] while there was no difference in neonatal complications (OR 0.83; 95% CI 0.56-1.21; P = 0.343). A limitation of our study is its retrospective design and the relatively small sample size, particularly in the AE-PCOS subgroup. Since women with PCOS have, regardless of the used definition, a high risk of maternal and neonatal complications they should be informed and advised to follow regular checks in units where problems can be detected early to allow specialized care. Marietta Blau Grant (Austrian Agency for International Cooperation in Education and Research; OeAD-GmbH) and mobility scholarship (Medical University of Graz). © The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email:
    Human Reproduction 07/2015; 30(10). DOI:10.1093/humrep/dev187 · 4.57 Impact Factor
Show more